The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global bio-implants market reached a value of US$ 98.9 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 8.5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Bio-implants are prostheses that are used for replacing, supporting or enhancing a biological structure. They are made up of different biosynthetic materials like collagen and tissue-engineered products like artificial skin. Bio-implants are majorly divided into three categories: biological implants that constitute bioartificial organs, cell therapy and tissue engineering; biologized implants that comprise of in-vivo cell lining, technical implants and biohybrid systems; and biofunctionalized implants that include surface-functionalized implants and drug-eluting stents. Bio-implants have been planted in various spheres of ENT and have resulted in some of the most successful surgical outcomes. They help to regularize physiological functions of patients which allows them to lead an efficient life.
The growth of the bio-implants market is driven by a rise in the geriatric population around the world which is the largest end-user of these implants. Moreover, technological advancements and increasing awareness about the success of cosmetic implantations are providing a positive thrust to the market growth. Further, as dental implants are one of the biggest contributors to the growth of the bio-implants market, an increase in dental issues across the globe is aiding the market growth. Additionally, cardiac pacemakers and orthopedic artificial implants are in constant demand owing to the growing prevalence of cardiovascular and orthopedic conditions.
IMARC Group provides an analysis of the key trends in each sub-segment of the global bio-implants market, along with forecasts at the global and regional level from 2021-2026. Our report has categorized the market based on type of bio-implants, material, origin, mode of administration and end-user.
Breakup by Type of Bio-Implants:
Based on the type of bio-implants, the market has been segmented into cardiovascular implants, dental implants, spinal bio-implants, orthopaedic implants, ophthalmic implants and others.
Breakup by Material:
Based on the type of material, the market has been segmented into metallic, ceramic, polymer and biological.
Breakup by Origin:
Based on the origin, the market has been segmented into allograft, autograft, xenograft and synthetic.
Breakup by Mode of Administration:
Based on the mode of administration, the market has been segmented into non-surgical and surgical.
Breakup by End-User:
Based on the end-user, the market has been segmented into ambulatory surgical centers, clinics, hospital and others.
Breakup by Region:
Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Boston Scientific Corporation, Stryker Corporation, St. Jude Medical Inc, Medtronic Inc., Smith and Nephew, Wright Medical Group, Zimmer Biomet, Dentsply Sirona, Invibio Limited, Straumann, Danaher Corporation, Cardinal Health, Johnson & Johnson, B. Braun Melsungen, LifeNet Health, Inc and Endo International plc.
|Base Year of the Analysis||2020|
|Segment Coverage||Type of Bio-Implants, Material, Origin, Mode of Administration, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Abbott Laboratories, Boston Scientific Corporation, Stryker Corporation, St. Jude Medical Inc, Medtronic Inc., Smith and Nephew, Wright Medical Group, Zimmer Biomet, Dentsply Sirona, Invibio Limited, Straumann, Danaher Corporation, Cardinal Health, Johnson & Johnson, B. Braun Melsungen, LifeNet Health, Inc and Endo International plc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at